相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications
Amy Ellen McCart Reed et al.
JOURNAL OF PATHOLOGY (2019)
The immunological consequences of radiation-induced DNA damage
Anna C. Wilkins et al.
JOURNAL OF PATHOLOGY (2019)
MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene
Jisun Kim et al.
JOURNAL OF PATHOLOGY (2018)
Is Age Trumping Genetic Profiling in Clinical Practice? Relationship of Chemotherapy Recommendation and Oncotype DX Recurrence Score in Patients Aged < 50 Years versus ≥ 50 Years, and Trends Over Time
Austin D. Williams et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Mechanisms of immune evasion in breast cancer
Joshua P. Bates et al.
BMC CANCER (2018)
Treatment of advanced HER2-positive breast cancer: 2018 and beyond
Noam Ponde et al.
CANCER TREATMENT REVIEWS (2018)
Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor
Sibylle Loibl et al.
CLINICAL CANCER RESEARCH (2018)
Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis
Matthew N. Mills et al.
EUROPEAN JOURNAL OF CANCER (2018)
Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance
Maryam Althobiti et al.
HISTOPATHOLOGY (2018)
Mixed ductal-lobular carcinomas: evidence for progression from ductal to lobular morphology
Amy E. McCart Reed et al.
JOURNAL OF PATHOLOGY (2018)
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
Angelo Di Leo et al.
LANCET ONCOLOGY (2018)
Solid papillary carcinoma with reverse polarity of the breast harbors specific morphologic, immunohistochemical and molecular profile in comparison with other benign or malignant papillary lesions of the breast: a comparative study of 9 additional cases
Nadjla Alsadoun et al.
MODERN PATHOLOGY (2018)
Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
Nikolaos Zacharakis et al.
NATURE MEDICINE (2018)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer
Xiaoling Puyang et al.
CANCER DISCOVERY (2018)
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer A Secondary Analysis of a Randomized Clinical Trial
Lvana Sestak et al.
JAMA ONCOLOGY (2018)
Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay
Michaela Tsai et al.
JAMA ONCOLOGY (2018)
Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)
Patrick Danaher et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives
Enrique Soto-Perez-De-Celis et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3
Massimo Cristofanilli et al.
EUROPEAN JOURNAL OF CANCER (2018)
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
N. C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Hypothesis: can the abscopal effect explain the impact of adjuvant radiotherapy on breast cancer mortality?
Ismail Jatoi et al.
NPJ BREAST CANCER (2018)
Towards predictive biomarkers for immunotherapy response in breast cancer patients
Leonie Voorwerk et al.
BREAST CANCER MANAGEMENT (2018)
Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer
Hehui Fang et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer
Jason. P. W. Carey et al.
CANCER RESEARCH (2018)
Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family
Felipe C. Geyer et al.
MODERN PATHOLOGY (2017)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Jose Baselga et al.
LANCET ONCOLOGY (2017)
Association analysis identifies 65 new breast cancer risk loci
Kyriaki Michailidou et al.
NATURE (2017)
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Helen Davies et al.
NATURE MEDICINE (2017)
Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer
Stephen J. Luen et al.
PATHOLOGY (2017)
Poly(ADP-ribose) polymerase activity and inhibition in cancer
Caleb Dulaney et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2017)
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1
Francois Bertucci et al.
CURRENT ONCOLOGY REPORTS (2017)
Prevalence and detection of low-allele-fraction variants in clinical cancer samples
Hyun-Tae Shin et al.
NATURE COMMUNICATIONS (2017)
Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer
Alberto Pelaez-Garcia et al.
PLOS ONE (2017)
Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast
Salvatore Piscuoglio et al.
NPJ BREAST CANCER (2017)
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer
Cynthia X. Ma et al.
CLINICAL CANCER RESEARCH (2017)
Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer
Zhi Ling Teo et al.
CANCER RESEARCH (2017)
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
David J. Messenheimer et al.
CLINICAL CANCER RESEARCH (2017)
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer
Uzma S. Asghar et al.
CLINICAL CANCER RESEARCH (2017)
Whole-Exome Sequencing of Metaplastic Breast Carcinoma Indicates Monoclonality with Associated Ductal Carcinoma Component
Bracha Erlanger Avigdor et al.
CLINICAL CANCER RESEARCH (2017)
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research
Shona Hendry et al.
ADVANCES IN ANATOMIC PATHOLOGY (2017)
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Shiping Jiao et al.
CLINICAL CANCER RESEARCH (2017)
The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas
Charlotte K. Y. Ng et al.
CLINICAL CANCER RESEARCH (2017)
Immunotherapy for Breast Cancer: What Are We Missing?
Robert H. Vonderheide et al.
CLINICAL CANCER RESEARCH (2017)
Dramatic response of metaplastic breast cancer to chemo-immunotherapy
Sylvia Adams
NPJ BREAST CANCER (2017)
Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay
Aleix Prat et al.
CLINICAL CANCER RESEARCH (2016)
Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies
Akira I. Hida et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study
Sara M. Tolaney et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
Shom Goel et al.
CANCER CELL (2016)
IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity
Sarah Chiang et al.
CANCER RESEARCH (2016)
Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer
In Hae Park et al.
CLINICAL BREAST CANCER (2016)
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling
Heather L. McArthur et al.
CLINICAL CANCER RESEARCH (2016)
OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer
Robert C. Stein et al.
HEALTH TECHNOLOGY ASSESSMENT (2016)
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3
Fabrice Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer
Charlotte Fribbens et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Lyndsay N. Harris et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Genomic Characterization of Primary Invasive Lobular Breast Cancer
Christine Desmedt et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations
Elena Guerini-Rocco et al.
JOURNAL OF PATHOLOGY (2016)
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
Richard Buus et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Serena Nik-Zainal et al.
NATURE (2016)
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
F. Cardoso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
G. N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
Klaus Okkenhaug et al.
CANCER DISCOVERY (2016)
ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas
Gabrielle Deniziaut et al.
ONCOTARGET (2016)
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
Richard Buus et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer A Secondary Analysis of the BOLERO-2 Clinical Trial
Sarat Chandarlapaty et al.
JAMA ONCOLOGY (2016)
Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants
Fresia Pareja et al.
NPJ BREAST CANCER (2016)
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
Giovanni Ciriello et al.
CELL (2015)
Novel agents and associated toxicities of inhibitors of the PI3K/Akt/mTOR pathway for the treatment of breast cancer
S. Chia et al.
CURRENT ONCOLOGY (2015)
Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score
Ivana Sestak et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance
Jodi M. Saunus et al.
JOURNAL OF PATHOLOGY (2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
M. Gnant et al.
ANNALS OF ONCOLOGY (2014)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S. Loi et al.
ANNALS OF ONCOLOGY (2014)
Association between CD8+T-cell infiltration and breast cancer survival in 12 439 patients
H. R. Ali et al.
ANNALS OF ONCOLOGY (2014)
Long-term impact of the 70-gene signature on breast cancer outcome
C. A. Drukker et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
L. Bracci et al.
CELL DEATH AND DIFFERENTIATION (2014)
A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer
Komal Jhaveri et al.
CLINICAL BREAST CANCER (2014)
The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer
Martin Filipits et al.
CLINICAL CANCER RESEARCH (2014)
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
Fabrice Andre et al.
LANCET ONCOLOGY (2014)
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
P. Dubsky et al.
ANNALS OF ONCOLOGY (2013)
Breast Cancer Index Identifies Early-Stage Estrogen Receptor-Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence
Yi Zhang et al.
CLINICAL CANCER RESEARCH (2013)
Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
Sherene Loi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population
Dennis C. Sgroi et al.
LANCET ONCOLOGY (2013)
Mutational landscape and significance across 12 major cancer types
Cyriac Kandoth et al.
NATURE (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers
Steven A. Roberts et al.
NATURE GENETICS (2013)
Deciphering Signatures of Mutational Processes Operative in Human Cancer
Ludmil B. Alexandrov et al.
CELL REPORTS (2013)
Effects of conventional therapeutic interventions on the number and function of regulatory T cells
Mario Roselli et al.
ONCOIMMUNOLOGY (2013)
Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines
D. M. Collins et al.
ANNALS OF ONCOLOGY (2012)
Mutational Processes Molding the Genomes of 21 Breast Cancers
Serena Nik-Zainal et al.
CELL (2012)
The Life History of 21 Breast Cancers
Serena Nik-Zainal et al.
CELL (2012)
IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives
Hui Yang et al.
CLINICAL CANCER RESEARCH (2012)
The landscape of cancer genes and mutational processes in breast cancer
Philip J. Stephens et al.
NATURE (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The immune contexture in human tumours: impact on clinical outcome
Wolf Herman Fridman et al.
NATURE REVIEWS CANCER (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
Shanu Modi et al.
CLINICAL CANCER RESEARCH (2011)
A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors
Martin Filipits et al.
CLINICAL CANCER RESEARCH (2011)
Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer
Jack Cuzick et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin
Kedar Hastak et al.
CANCER RESEARCH (2010)
A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer
Torsten O. Nielsen et al.
CLINICAL CANCER RESEARCH (2010)
American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Histological features of medullary carcinoma and prognosis in triple-negative basal-like carcinomas of the breast
Felicia Marginean et al.
MODERN PATHOLOGY (2010)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH (2009)
Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group
Robert J. Paridaens et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Augmented HER-2-Specific immunity during treatment with trastuzumab and chemotherapy
Clare Taylor et al.
CLINICAL CANCER RESEARCH (2007)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance
Mark Barok et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Letrozole in advanced breast cancer: the PO25 trial
Henning T. Mouridsen
BREAST CANCER RESEARCH AND TREATMENT (2007)
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
Kenneth R. Hess et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
Marc Buyse et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis
C Sotiriou et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A gene-expression signature as a predictor of survival in breast cancer.
MJ van de Vijver et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment
A Howell et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Gene expression profiling predicts clinical outcome of breast cancer
LJ van't Veer et al.
NATURE (2002)
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
JM Nabholtz et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
